# Capricor Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/capricor-therapeutics

- Industry: Biotechnology
- Headquarters: Beverly Hills, US
- Website: www.capricor.com
- Total disclosed funding: $2M
- Latest round: Series A (Dec 20, 2010)
- Investors on record: 1

## About

Capricor Therapeutics, Inc. is a biopharmaceutical firm focused on developing innovative therapies for Duchenne muscular dystrophy and other severe diseases through advanced cell and exosome-based technology.Founded in 2005 in Beverly Hills, US, Capricor Therapeutics, Inc. specializes in developing biopharmaceutical products. The company has completed 6 funding deals, with the latest being a Grant of USD 2.4 mn from the U.S. Department of Defense in September 2016. The total amount raised by the company is USD 26.2 mn. Capricor has been led by CEO Linda Marban, who has a background in biotechnology and previously founded other ventures in the field.Capricor Therapeutics, Inc. specializes in innovative biopharmaceutical products aimed at treating Duchenne muscular dystrophy (DMD) and a variety of other severe diseases through advanced cell and exosome-based therapies. Their core offerings include allogeneic cardiosphere-derived cells (CDCs) and exosome science, which are utilized to create novel therapeutic approaches that address critical unmet medical needs. The company's pipeline encompasses multiple stages of development, focusing on precision medicine tailored to individual patient profiles. Capricor Therapeutics serves healthcare providers and research institutions across North America and Europe, where their products are being explored in clinical trials and therapeutic applications.In 2023, Capricor Therapeutics reported a revenue of USD 25.18 mn. The company also recorded an EBITDA of USD -23.01 mn during the same year. Revenue is generated primarily through collaborations, partnerships, and clinical trial agreements with various stakeholders in the biopharmaceutical landscape, including licensing agreements and potential milestone payments from partners as products progress through clinical development stages.Capricor Therapeutics plans to utilize the recent Grant funding of USD 2.4 mn from the U.S. Department of Defense to support the development of new products aimed at treating severe diseases. The company is focused on expanding its market presence into new geographic regions, including North America and Europe, by 2024. Additionally, Capricor is actively working on advancing its pipeline of exosome-based therapeutics, which are designed to meet critical health needs, with ongoing clinical trials to evaluate their efficacy.

## Funding rounds

- Series A, Dec 20, 2010, $2M — Broadview Ventures

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series A